Paper41789650
Targeting poly(ADP-ribose) polymerase in metastatic prostate cancer: current landscape and future directions.
Shi X and 3 others. Curr Opin Oncol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Targeting poly(ADP-ribose) polymerase in metastatic prostate cancer: current landscape and future directions. Papers, record 41789650. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41789650
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Targeting poly(ADP-ribose) polymerase in metastatic prostate cancer: current landscape and future directions.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Poly(ADP-ribose) Polymerase Inhibitors | Major topic |
| Prostatic Neoplasms, Castration-Resistant | Major topic |
| Prostatic Neoplasms | Major topic |
| Humans | |
| Male | |
| Neoplasm Metastasis |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA134274 | NCI NIH HHS | United States | P30CA134274 | PubMed | NIH RePORTER |
| T32 CA154274 | NCI NIH HHS | United States | T32CA154274 | PubMed | NIH RePORTER |
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32955174 | Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32955174 | PubMed |
| 2 | 37963304 | Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/37963304 | PubMed |
| 3 | 35279473 | Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors. | Eur J Cancer | 2022 | https://conductscience.org/library/papers/35279473 | PubMed |
| 4 | 40683287 | Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. | Lancet | 2025 | https://conductscience.org/library/papers/40683287 | PubMed |
| 5 | 40086424 | Deciphering the mechanisms of PARP inhibitor resistance in prostate cancer: Implications for precision medicine. | Biomed Pharmacother | 2025 | https://conductscience.org/library/papers/40086424 | PubMed |
| 6 | 28811666 | The essential kinase ATR: ensuring faithful duplication of a challenging genome. | Nat Rev Mol Cell Biol | 2017 | https://conductscience.org/library/papers/28811666 | PubMed |
| 7 | 31659317 | Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation. | Nat Chem Biol | 2019 | https://conductscience.org/library/papers/31659317 | PubMed |
| 8 | 21383736 | Targeting the missing links for cancer therapy. | Nat Med | 2011 | https://conductscience.org/library/papers/21383736 | PubMed |
| 9 | 30345412 | Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer. | Annu Rev Cancer Biol | 2018 | https://conductscience.org/library/papers/30345412 | PubMed |
| 10 | 37290035 | Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/37290035 | PubMed |
| 11 | 38319800 | Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. | NEJM Evid | 2022 | https://conductscience.org/library/papers/38319800 | PubMed |
| 12 | 40582078 | Expanding PARP Inhibitor Use in Prostate Cancer Beyond DNA Repair Defects. | Clin Oncol (R Coll Radiol) | 2025 | https://conductscience.org/library/papers/40582078 | PubMed |
| 13 | 32123273 | Androgen Receptor and Poly(ADP-ribose) Glycohydrolase Inhibition Increases Efficiency of Androgen Ablation in Prostate Cancer Cells. | Sci Rep | 2020 | https://conductscience.org/library/papers/32123273 | PubMed |
| 14 | 37882449 | TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. | Future Oncol | 2024 | https://conductscience.org/library/papers/37882449 | PubMed |
| 15 | 39848867 | Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis. | Eur Urol | 2025 | https://conductscience.org/library/papers/39848867 | PubMed |
| 16 | 12933815 | Role of XRCC1 in the coordination and stimulation of oxidative DNA damage repair initiated by the DNA glycosylase hOGG1. | J Biol Chem | 2003 | https://conductscience.org/library/papers/12933815 | PubMed |
| 17 | 37126020 | Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes. | Clin Cancer Res | 2023 | https://conductscience.org/library/papers/37126020 | PubMed |
| 18 | 28851861 | Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. | Nat Commun | 2017 | https://conductscience.org/library/papers/28851861 | PubMed |
| 19 | 36650183 | CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. | Nat Commun | 2023 | https://conductscience.org/library/papers/36650183 | PubMed |
| 20 | 36361678 | PTEN Loss Enhances Error-Prone DSB Processing and Tumor Cell Radiosensitivity by Suppressing RAD51 Expression and Homologous Recombination. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36361678 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRCA1 | 672 | PubTator's text mining | https://conductscience.org/library/genes/672 | NCBI Gene |
| PARP1 | 142 | PubTator's text mining | https://conductscience.org/library/genes/142 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41789650
GET https://conductscience.org/api/papers/v1/41789650/references?page=2